Biovitrum in deal for three Amgen drugs

Biovitrum (SSE:BVT) will acquire marketed products Kepivance palifermin and Stemgen ancestim from Amgen (NASDAQ:AMGN). The deal also includes an

Read the full 190 word article

How to gain access

Continue reading with a
two-week free trial.